Cargando…

Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance

BACKGROUND: Little is known about genetic basis and proteomics in valvular heart disease (VHD) including rheumatic (RVD) and degenerative (DVD) valvular disease. The present proteomic study examined the hypothesis that certain proteins may be associated with the pathological changes in the plasma of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ge, Xuan, Chao, Yang, Qin, Liu, Xiao-Cheng, Liu, Zhi-Gang, He, Guo-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754973/
https://www.ncbi.nlm.nih.gov/pubmed/24015209
http://dx.doi.org/10.1371/journal.pone.0072111
_version_ 1782281941148499968
author Gao, Ge
Xuan, Chao
Yang, Qin
Liu, Xiao-Cheng
Liu, Zhi-Gang
He, Guo-Wei
author_facet Gao, Ge
Xuan, Chao
Yang, Qin
Liu, Xiao-Cheng
Liu, Zhi-Gang
He, Guo-Wei
author_sort Gao, Ge
collection PubMed
description BACKGROUND: Little is known about genetic basis and proteomics in valvular heart disease (VHD) including rheumatic (RVD) and degenerative (DVD) valvular disease. The present proteomic study examined the hypothesis that certain proteins may be associated with the pathological changes in the plasma of VHD patients. METHODS AND RESULTS: Differential protein analysis in the plasma identified 18 differentially expressed protein spots and 14 corresponding proteins or polypeptides by two-dimensional electrophoresis and mass spectrometry in 120 subjects. Two up-regulated (complement C4A and carbonic anhydrase 1) and three down-regulated proteins (serotransferrin, alpha-1-antichymotrypsin, and vitronectin) were validated by ELISA in enlarging samples. The plasma levels (n = 40 for each) of complement C4A in RVD (715.8±35.6 vs. 594.7±28.2 ng/ml, P = 0.009) and carbonic anhydrase 1 (237.70±15.7 vs. 184.7±10.8 U/L, P = 0.007) in DVD patients were significantly higher and that of serotransferrin (2.36±0.20 vs. 2.93±0.16 mg/ml, P = 0.025) and alpha-1-antichymotrypsin (370.0±13.7 vs. 413.0±11.6 µg/ml, P = 0.019) in RVD patients were significantly lower than those in controls. The plasma vitronectin level in both RVD (281.3±11.0 vs. 323.2±10.0 µg/ml, P = 0.006) and DVD (283.6±11.4 vs. 323.2±10.0 µg/ml, P = 0.011) was significantly lower than those in normal controls. CONCLUSIONS: We have for the first time identified alterations of 14 differential proteins or polypeptides in the plasma of patients with various VHD. The elevation of plasma complement C4A in RVD and carbonic anhydrase 1 in DVD and the decrease of serotransferrin and alpha-1-antichymotrypsin in RVD patients may be useful biomarkers for these valvular diseases. The decreased plasma level of vitronectin – a protein related to the formation of valvular structure – in both RVD and DVD patients might indicate the possible genetic deficiency in these patients.
format Online
Article
Text
id pubmed-3754973
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37549732013-09-06 Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance Gao, Ge Xuan, Chao Yang, Qin Liu, Xiao-Cheng Liu, Zhi-Gang He, Guo-Wei PLoS One Research Article BACKGROUND: Little is known about genetic basis and proteomics in valvular heart disease (VHD) including rheumatic (RVD) and degenerative (DVD) valvular disease. The present proteomic study examined the hypothesis that certain proteins may be associated with the pathological changes in the plasma of VHD patients. METHODS AND RESULTS: Differential protein analysis in the plasma identified 18 differentially expressed protein spots and 14 corresponding proteins or polypeptides by two-dimensional electrophoresis and mass spectrometry in 120 subjects. Two up-regulated (complement C4A and carbonic anhydrase 1) and three down-regulated proteins (serotransferrin, alpha-1-antichymotrypsin, and vitronectin) were validated by ELISA in enlarging samples. The plasma levels (n = 40 for each) of complement C4A in RVD (715.8±35.6 vs. 594.7±28.2 ng/ml, P = 0.009) and carbonic anhydrase 1 (237.70±15.7 vs. 184.7±10.8 U/L, P = 0.007) in DVD patients were significantly higher and that of serotransferrin (2.36±0.20 vs. 2.93±0.16 mg/ml, P = 0.025) and alpha-1-antichymotrypsin (370.0±13.7 vs. 413.0±11.6 µg/ml, P = 0.019) in RVD patients were significantly lower than those in controls. The plasma vitronectin level in both RVD (281.3±11.0 vs. 323.2±10.0 µg/ml, P = 0.006) and DVD (283.6±11.4 vs. 323.2±10.0 µg/ml, P = 0.011) was significantly lower than those in normal controls. CONCLUSIONS: We have for the first time identified alterations of 14 differential proteins or polypeptides in the plasma of patients with various VHD. The elevation of plasma complement C4A in RVD and carbonic anhydrase 1 in DVD and the decrease of serotransferrin and alpha-1-antichymotrypsin in RVD patients may be useful biomarkers for these valvular diseases. The decreased plasma level of vitronectin – a protein related to the formation of valvular structure – in both RVD and DVD patients might indicate the possible genetic deficiency in these patients. Public Library of Science 2013-08-27 /pmc/articles/PMC3754973/ /pubmed/24015209 http://dx.doi.org/10.1371/journal.pone.0072111 Text en © 2013 Gao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gao, Ge
Xuan, Chao
Yang, Qin
Liu, Xiao-Cheng
Liu, Zhi-Gang
He, Guo-Wei
Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance
title Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance
title_full Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance
title_fullStr Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance
title_full_unstemmed Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance
title_short Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance
title_sort identification of altered plasma proteins by proteomic study in valvular heart diseases and the potential clinical significance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754973/
https://www.ncbi.nlm.nih.gov/pubmed/24015209
http://dx.doi.org/10.1371/journal.pone.0072111
work_keys_str_mv AT gaoge identificationofalteredplasmaproteinsbyproteomicstudyinvalvularheartdiseasesandthepotentialclinicalsignificance
AT xuanchao identificationofalteredplasmaproteinsbyproteomicstudyinvalvularheartdiseasesandthepotentialclinicalsignificance
AT yangqin identificationofalteredplasmaproteinsbyproteomicstudyinvalvularheartdiseasesandthepotentialclinicalsignificance
AT liuxiaocheng identificationofalteredplasmaproteinsbyproteomicstudyinvalvularheartdiseasesandthepotentialclinicalsignificance
AT liuzhigang identificationofalteredplasmaproteinsbyproteomicstudyinvalvularheartdiseasesandthepotentialclinicalsignificance
AT heguowei identificationofalteredplasmaproteinsbyproteomicstudyinvalvularheartdiseasesandthepotentialclinicalsignificance